We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Fusion Antibodies Awarded Platinum Level Innovator Status by Innovate NI
Product News

Fusion Antibodies Awarded Platinum Level Innovator Status by Innovate NI

Fusion Antibodies Awarded Platinum Level Innovator Status by Innovate NI
Product News

Fusion Antibodies Awarded Platinum Level Innovator Status by Innovate NI

Credit: Fusion Antibodies

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Fusion Antibodies Awarded Platinum Level Innovator Status by Innovate NI"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The scheme recognises businesses across Northern Ireland who have shown innovation in their processes, products and or services. The platinum level indicates Fusion Antibodies have secured commercial benefits from their innovation. Fusion Antibodies have received this certification for their innovative antibody engineering and discovery platforms which have been developed based on their own intelligent design.

The Programme aims to highlight the importance of innovation for business growth, create more awareness of the value of innovation, as well as how to innovate. The ultimate goal is to increase the number of Northern Ireland businesses successfully engaging in innovation activity.

On receiving the award Dr Richard Jones, CEO of Fusion Antibodies, said: “We are delighted to receive this award and I would like to thank our tremendous team who embody the spirit of innovation. At Fusion we are continuously innovating to enhance our capability to deliver services and solutions that allow our clients to develop the best possible antibodies against their target getting them closer to their end goal; the provision of treatments that improve the lives of patients throughout the world.

“Unlike many of our competition, our library design approach explores the natural hypermutation space; in essence, we believe that when it comes to engineering antibodies, the sequence should be kept as natural as possible and so ‘mimics’ the human system.

“I am immensely proud of what everyone has worked so hard together to achieve. It’s a great way to start 2021 which promises to be another exciting year for the company, with a number of new exciting developments already in the pipeline.”

Economy Minister Diane Dodds said: “The Innovation Accreditation Programme supports businesses to invest in innovation and improve their competitiveness. The scheme emphasises the value of innovation for business growth. Innovation is so important at this difficult time because it is essential to economic recovery. I want to congratulation Fusion Antibodies on this award and on their work on in advancing the life sciences sector.”

Congratulating the company, Dr Vicky Kell, Invest NI’s Director of Innovation, Research & Development said: “Fusion Antibodies is a highly innovative company which has benefitted from Invest NI support for R&D to position itself as a world leader in antibody development.

“It has never been more critical to support innovation within the life sciences industry and Fusion Antibodies is an excellent example of an organisation recognising the importance of investing in R&D to maintain a competitive business beyond COVID-19.

“It is great to see the company’s hard work, effort and determination being recognised through the Innovation Accreditation Programme.

“Platinum is the highest achievable accolade awarded through the Innovation Accreditation Programme and recognises how Fusion Antibodies, through its cutting-edge research and development strategy, has created value for its business. This culture of innovation will undoubtedly lead to future success and I look forward to following their innovation journey.” 

Advertisement